GRI Bio annual stock-based compensation
2020
2021
2022
2023
2024
2025
GRI Bio Stock-Based Compensation Growth & History (GRI)
GRI Bio's stock-based compensation was $793,000 for fiscal 2025.
View full GRI Bio company overviewGRI Bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $793,000 | $645,000 | +435.81% |
| 2024 | 2024-12-31 | $148,000 | −$240,000 | −61.86% |
| 2023 | 2023-12-31 | $388,000 | $363,000 | +1452.00% |
| 2022 | 2022-12-31 | $25,000 | −$601,000 | −96.01% |
| 2021 | 2021-12-31 | $626,000 | $472,000 | +306.49% |
| 2020 | 2020-12-31 | $154,000 | — | — |
GRI Bio quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $33,000 | −$8,000 | −19.51% |
| Q1 2026 | 2026-03-31 | $31,000 | −$189,000 | −85.91% |
| Q4 2025 | 2025-12-31 | $67,000 | $30,000 | +81.08% |
| Q3 2025 | 2025-09-30 | $465,000 | $428,000 | +1156.76% |
| Q2 2025 | 2025-06-30 | $41,000 | $4,000 | +10.81% |
| Q1 2025 | 2025-03-31 | $220,000 | $183,000 | +494.59% |
| Q4 2024 | 2024-12-31 | $37,000 | $1,000 | +2.78% |
| Q3 2024 | 2024-09-30 | $37,000 | −$289,000 | −88.65% |
| Q2 2024 | 2024-06-30 | $37,000 | $24,000 | +184.62% |
| Q1 2024 | 2024-03-31 | $37,000 | $24,000 | +184.62% |
| Q4 2023 | 2023-12-31 | $36,000 | — | — |
| Q3 2023 | 2023-09-30 | $326,000 | $326,000 | — |
| Q2 2023 | 2023-06-30 | $13,000 | $13,000 | — |
| Q1 2023 | 2023-03-31 | $13,000 | −$168,000 | −92.82% |
| Q3 2022 | 2022-09-30 | $0 | −$134,000 | — |
| Q2 2022 | 2022-06-30 | $0 | −$138,000 | — |
| Q1 2022 | 2022-03-31 | $181,000 | $13,000 | +7.74% |
| Q4 2021 | 2021-12-31 | $626,000 | $472,000 | +306.49% |
| Q3 2021 | 2021-09-30 | $134,000 | $82,000 | +157.69% |
| Q2 2021 | 2021-06-30 | $138,000 | $110,000 | +392.86% |
| Q1 2021 | 2021-03-31 | $168,000 | $133,000 | +380.00% |
| Q4 2020 | 2020-12-31 | $154,000 | — | — |
| Q3 2020 | 2020-09-30 | $52,000 | — | — |
| Q2 2020 | 2020-06-30 | $28,000 | — | — |
| Q1 2020 | 2020-03-31 | $35,000 | — | — |
GRI Bio stock-based compensation trends
Over the last five fiscal years, GRI Bio's stock-based compensation increased from $154,000 to $793,000, a change of $639,000. The latest reported quarter, Q2 2026, shows $33,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GRI Bio source filings ↗